Diffusion-weighted MRI imaging is part of multiparametric MRI imaging mpMRI, which is the current technology to distinguish significant PCa from insignificant PCa with high accuracy. Without diffusion-weighted imaging it’s not mpMRI and the imaging will only poorly be able to distinguish significant from insignificant PCa. This is all explained in a 55-page article published by the American College of Radiology available online by searching for: PI-RADS v2
I copied only the first few paragraphs of that article’s INTRODUCTION, below:
[Sub-title] Prostate Imaging and Reporting and Data System: Version 2
INTRODUCTION
Magnetic Resonance Imaging (MRI) has been used for noninvasive assessment of the prostate gland and surrounding structures since the 1980s. Initially, prostate MRI was based solely on morphologic assessment using T1-weighted (T1W) and T2-weighted (T2W) pulse sequences, and its role was primarily for locoregional staging in patients with biopsy proven cancer. However, it provided limited capability to distinguish benign pathological tissue and clinically insignificant prostate cancer from significant cancer.
Advances in technology (both in software and hardware) have led to the development of multiparametric MRI (mpMRI), which combines anatomic T2W with functional and physiologic assessment, including diffusion-weighted imaging (DWI) and its derivative apparent-diffusion coefficient (ADC) maps, dynamic contrast-enhanced (DCE) MRI, and sometimes other techniques such as in-vivo MR proton spectroscopy. These technologic advances, combined with a growing interpreter experience with mpMRI, have substantially improved diagnostic capabilities for addressing the central challenges in prostate cancer care: 1) Improving detection of clinically significant cancer, which is critical for reducing mortality; and 2) Increasing confidence in benign diseases and dormant malignancies, which are not likely to cause problems in a man’s lifetime, in order to reduce unnecessary biopsies and treatment.
Consequently, clinical applications of prostate MRI have expanded to include, not only locoregional staging, but also tumor detection, localization (registration against an anatomical reference), characterization, risk stratification, surveillance, assessment of suspected recurrence, and image guidance for biopsy, surgery, focal therapy and radiation therapy.
In 2007, recognizing an important evolving role for MRI in assessment of prostate cancer, the AdMeTech Foundation organized the International Prostate MRI Working Group, which brought together key leaders of academic research and industry. Based on deliberations by this group, a research strategy was developed and a number of critical impediments to the widespread acceptance and use of MRI were identified. Amongst these was excessive variation in the performance, interpretation, and reporting of prostate MRI exams. A greater level of standardization and consistency was recommended in order to facilitate multi-center clinical evaluation and implementation.
Harvey in Southern California.
I had an mpMRI in Jan, 2015, in Thousand Oaks, California, after a scary leap of PSA from 8.5 to 14. The reading came back as PI-RADS 2 (out of 5), which is: Low (clinically significant cancer is unlikely to be present), so I had no biopsy taken. A month later my PSA zoomed back down to 8.5, where it has remained since, approximately.